Why Is AdaptHealth Corp. (AHCO) Stock Down -40.72% Today?
Key Takeaways
- AHCO shares plunged approximately 40.72% in Tuesday's trading session following the company's Q2 2026 earnings release.
- The primary catalyst was a massive earnings miss: AdaptHealth reported a loss of $0.99 per share versus analyst expectations of a $0.15 profit, alongside revenue of $740.3 million that fell well short of the $848 million consensus.
- A $144.2 million non-cash goodwill impairment charge drove the company deep into the red, producing a net loss of $145.3 million.
- Full-year guidance was slashed dramatically, with revenue now expected between $2.85 billion and $2.89 billion, down sharply from the prior $3.49 billion midpoint and well below Wall Street estimates.
- Margin compression from a troubled West Coast capitated contract and manufacturer price increases further weighed on profitability and the outlook.
- Traders are now watching for signs of stabilization in the capitated contract performance, the closing of the Diabetes Health divestiture to Cardinal Health, and any further restructuring announcements.
Opening Summary
Shares of AHCO, AdaptHealth Corp.—a leading provider of home medical equipment, supplies, and related services for patients managing chronic conditions such as sleep apnea, respiratory disorders, and diabetes—collapsed approximately 40.72% on Tuesday. The stock last traded around $6.42, down from Monday's close of $10.83. The selloff was triggered by a deeply disappointing second-quarter 2026 earnings report that missed Wall Street expectations by a wide margin and included a sharp reduction in full-year guidance, sending shockwaves through the market.
Earnings Results Deeply Disappoint
AdaptHealth reported Q2 2026 net revenue of $740.3 million, representing 12.7% year-over-year growth but falling significantly short of the consensus estimate near $848 million. While the company highlighted organic revenue growth of 15.9%—its strongest quarterly rate in more than a year—the top-line figure disappointed as the market had anticipated a substantially larger contribution from the company's continuing operations.
The bottom line was where the damage was most severe. AdaptHealth posted an adjusted loss of $0.99 per share, compared with analyst expectations for a profit of $0.15 per share. On a GAAP basis, the net loss attributable to AdaptHealth reached $145.3 million, a stark reversal from net income of $4.2 million in the prior-year period. The primary driver of the loss was a non-cash goodwill impairment charge of $144.2 million, which management attributed to a reassessment of valuations in the Respiratory Health and Wellness at Home reporting units following portfolio changes and evolving market conditions.
Guidance Cut Rattles Investor Confidence
Perhaps even more damaging than the quarterly miss was management's decision to dramatically lower its full-year 2026 outlook for continuing operations. The company now expects net revenue between $2.85 billion and $2.89 billion—down from the prior midpoint of roughly $3.49 billion and well below the analyst consensus. Adjusted EBITDA guidance was reduced to a range of $490 million to $520 million, while free cash flow is now projected at just $80 million to $120 million for the full year.
Management pointed to several headwinds behind the guidance cut: approximately $55 million in costs tied to ramping a large West Coast capitated contract, an estimated $30 million impact from manufacturer price increases effective July 1, and about $15 million in costs related to portfolio rationalization. The sale of the Diabetes Health business to CAH for $235 million in cash—announced concurrently—will also remove roughly $100 million in revenue, including corporate overhead that will remain with AdaptHealth post-divestiture.
Margin Compression and Operational Challenges
Despite delivering robust volume growth across its core Sleep Health and Respiratory Health segments, AdaptHealth's profitability came under severe pressure in the quarter. Adjusted EBITDA declined 3.2% year over year to $132.0 million, while the adjusted EBITDA margin compressed to 17.8% from 20.8% a year earlier. The West Coast capitated contract alone created a $55 million EBITDA headwind, with management acknowledging that roughly two-thirds of that was driven by higher-than-expected patient volumes and the remainder tied to elevated labor and logistics costs.
Free cash flow turned negative, reaching negative $20.9 million in the quarter, as capital expenditures of $166.2 million outstripped operating cash flow of $145.3 million. The company's leverage remains elevated, with total long-term debt of $1.94 billion against unrestricted cash of just $43.3 million and a consolidated leverage ratio of 3.06 times adjusted EBITDA—above management's long-term target range.
Market Context and Trading Activity
The magnitude of the decline placed AHCO among the market's worst performers for the session, with volume surging well above the daily average as investors rushed to reprice the stock. The selloff pushed shares near the lower end of their 52-week range of approximately $6.14 to $13.43. The move was idiosyncratic rather than sector-driven, as broader healthcare indices and the Nasdaq Composite did not exhibit comparable weakness. The company's market capitalization contracted sharply, and the stock now trades more than 51% below its April 2026 peak.
What Comes Next for AHCO
Investors will be closely monitoring the progress of the problematic West Coast capitated contract, which management expects to improve gradually over the next several quarters and reach long-term margin targets by 2027. The closing of the Diabetes Health divestiture to Cardinal Health is expected to provide a cash infusion of $235 million, with proceeds earmarked in part for debt reduction. Key risks include the potential for further margin erosion if cost pressures persist, the execution risk of the company's strategic pivot toward Sleep and Respiratory Health, and the ongoing burden of elevated leverage. With the stock now trading at deeply depressed levels, the next several quarters will be critical in determining whether management can restore profitability and rebuild credibility with the investor community.
Trending AI Robots
For traders seeking systematic, data-driven approaches to navigating volatile markets, Tickeron's Trending AI Robots page offers access to hundreds of AI-powered trading bots covering thousands of tickers. Only the strongest-performing bots under current market conditions are featured in this curated section, with each bot differentiated by strategy, timeframe, performance metrics, and the symbols it trades. Exploring this resource can help investors discover automated trading tools aligned with their specific market outlook and risk tolerance.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Financial analyst and market blogger with expertise in equity research, fundamental analysis, and macroeconomic trends. I regularly publish coverage on individual stocks, ETFs, and sector developments — combining rigorous financial analysis with clear, engaging writing for a broad investment audience.
AHCO sees its Stochastic Oscillator ascends from oversold territory
On October 01, 2026, the Stochastic Oscillator for AHCO moved out of oversold territory and this could be a bullish sign for the stock. Traders may want to buy the stock or buy call options. Tickeron's A.I.dvisor looked at 66 instances where the indicator left the oversold zone. In 53 of the 66 cases the stock moved higher in the following days. This puts the odds of a move higher at over 80%.
Technical Analysis (Indicators)
Bullish Trend Analysis
Following a +0.53% 3-day Advance, the price is estimated to grow further. Considering data from situations where AHCO advanced for three days, in 226 of 300 cases, the price rose further within the following month. The odds of a continued upward trend are 75%.
The Aroon Indicator entered an Uptrend today. In 132 of 184 cases where AHCO Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 72%.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on September 24, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on AHCO as a result. In 70 of 92 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 76%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where AHCO declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 81%.
AHCO broke above its upper Bollinger Band on September 02, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 49 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 57 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.547) is normal, around the industry mean (10.853). P/E Ratio (16.491) is within average values for comparable stocks, (98.910). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (11.052). Dividend Yield (0.000) settles around the average of (0.002) among similar stocks. P/S Ratio (0.240) is also within normal values, averaging (39.828).
The Tickeron Price Growth Rating for this company is 87 (best 1 - 100 worst), indicating slightly worse than average price growth. AHCO’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 94 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. AHCO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 96, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a provider of medical products for both rental and sale
Industry MedicalNursingServices
Advertisement